Randy Robinson

2.1k total citations
31 papers, 1.5k citations indexed

About

Randy Robinson is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Randy Robinson has authored 31 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 12 papers in Oncology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Randy Robinson's work include Monoclonal and Polyclonal Antibodies Research (11 papers), HER2/EGFR in Cancer Research (8 papers) and Immunotherapy and Immune Responses (7 papers). Randy Robinson is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (11 papers), HER2/EGFR in Cancer Research (8 papers) and Immunotherapy and Immune Responses (7 papers). Randy Robinson collaborates with scholars based in United States, Australia and Spain. Randy Robinson's co-authors include Chun‐Wei Chang, Arnold H. Horwitz, Marc Better, Euan Murray, Norman Davidson, Ingegerd Hellström, K E Hellström, Jane R. Parnes, Jonathan G. Seidman and J A Ledbetter and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Randy Robinson

31 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Randy Robinson United States 13 773 767 479 368 237 31 1.5k
Christopher Coleclough United States 23 486 0.6× 548 0.7× 1.3k 2.7× 299 0.8× 210 0.9× 37 2.0k
I Hellström United States 18 656 0.8× 585 0.8× 671 1.4× 418 1.1× 75 0.3× 37 1.4k
Craig Okada United States 20 407 0.5× 760 1.0× 1.7k 3.4× 749 2.0× 460 1.9× 49 2.6k
Gerard Folch Spain 5 307 0.4× 725 0.9× 553 1.2× 365 1.0× 111 0.5× 6 1.4k
Irene Leung United States 13 621 0.8× 625 0.8× 444 0.9× 252 0.7× 54 0.2× 30 1.2k
Kay Stubenrauch Germany 16 883 1.1× 757 1.0× 446 0.9× 224 0.6× 27 0.1× 33 1.4k
Aurelia Rughetti Italy 27 312 0.4× 954 1.2× 1.0k 2.1× 622 1.7× 67 0.3× 81 1.9k
Joann P. Palma United States 21 120 0.2× 563 0.7× 377 0.8× 706 1.9× 145 0.6× 41 1.4k
R A Reisfeld United States 18 629 0.8× 805 1.0× 480 1.0× 315 0.9× 26 0.1× 28 1.3k
Christopher Stebbins United States 20 425 0.5× 615 0.8× 1.8k 3.7× 366 1.0× 70 0.3× 30 2.2k

Countries citing papers authored by Randy Robinson

Since Specialization
Citations

This map shows the geographic impact of Randy Robinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Randy Robinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Randy Robinson more than expected).

Fields of papers citing papers by Randy Robinson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Randy Robinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Randy Robinson. The network helps show where Randy Robinson may publish in the future.

Co-authorship network of co-authors of Randy Robinson

This figure shows the co-authorship network connecting the top 25 collaborators of Randy Robinson. A scholar is included among the top collaborators of Randy Robinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Randy Robinson. Randy Robinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cooper, Alissa J., Sreenivasa R Chandana, Muhammad Furqan, et al.. (2025). Safety and efficacy of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in high-grade neuroendocrine neoplasms.. Journal of Clinical Oncology. 43(16_suppl). 105–105. 2 indexed citations
2.
Chandana, Sreenivasa R, Noura J. Choudhury, Afshin Dowlati, et al.. (2024). First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3001–3001. 10 indexed citations
3.
4.
Chandana, Sreenivasa R, Benjamin Garmezy, Afshin Dowlati, et al.. (2023). 2029TiP Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors. Annals of Oncology. 34. S1077–S1077. 3 indexed citations
5.
Demetri, George D., Jason J. Luke, Antoine Hollebecque, et al.. (2021). First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clinical Cancer Research. 27(13). 3556–3566. 41 indexed citations
6.
Kappos, Ludwig, Stanley Cohan, Douglas L. Arnold, et al.. (2021). Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination. Therapeutic Advances in Neurological Disorders. 14. 1279209509–1279209509. 4 indexed citations
7.
Gold, Ralf, Ernst‐Wilhelm Radue, Gavin Giovannoni, et al.. (2020). Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. Journal of Neurology. 267(10). 2851–2864. 8 indexed citations
8.
Demetri, George D., Jason J. Luke, Antoine Hollebecque, et al.. (2019). First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 3004–3004. 12 indexed citations
9.
10.
Sheridan, James P., Randy Robinson, & John Rose. (2013). Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis. Expert Review of Clinical Pharmacology. 7(1). 9–19. 6 indexed citations
11.
Gold, Ralf, Gavin Giovannoni, Krzysztof Selmaj, et al.. (2013). Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. The Lancet. 381(9884). 2167–2175. 218 indexed citations
12.
Yeh, Steven, Keith J. Wroblewski, Ronald Buggage, et al.. (2008). High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. Journal of Autoimmunity. 31(2). 91–97. 54 indexed citations
13.
Sun, Wei, Hong Nie, Ying C. Q. Zang, et al.. (2005). Skewed T-cell receptor BV14 and BV16 expression and shared CDR3 sequence and common sequence motifs in synovial T cells of rheumatoid arthritis. Genes and Immunity. 6(3). 248–261. 29 indexed citations
14.
Centola, Michael, et al.. (1996). Production of anti-erythrocyte antibodies by leukemic and nonleukemic b cells in chronic lymphocytic leukemia patients. Leukemia & lymphoma. 20(5-6). 465–469. 9 indexed citations
15.
Albertini, Mark R., David F. Gibson, Simon P. Robinson, et al.. (1992). Influence of Estradiol and Tamoxifen on Susceptibility of Human Breast Cancer Cell Lines to Lysis by Lymphokine-Activated Killer Cells. Journal of Immunotherapy. 11(1). 30–39. 8 indexed citations
16.
Robinson, Randy, et al.. (1991). Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities. Human Antibodies. 2(2). 84–93. 12 indexed citations
17.
Better, Marc, Chun‐Wei Chang, Randy Robinson, & Arnold H. Horwitz. (1988). Escherichia coli Secretion of an Active Chimeric Antibody Fragment. Science. 240(4855). 1041–1043. 441 indexed citations
18.
Robinson, Randy, et al.. (1987). Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.. The Journal of Immunology. 139(10). 3521–3526. 122 indexed citations
19.
Mixter, Philip F., S. Vincent Wu, Gary M. Studnicka, & Randy Robinson. (1986). A simple, computer-assisted assay to detect isotype-specific regulation of human immunoglobulin synthesis. Journal of Immunological Methods. 91(2). 195–203. 4 indexed citations
20.
Parnes, Jane R., Randy Robinson, & Jonathan G. Seidman. (1983). Multiple mRNA species with distinct 3′ termini are transcribed from the β2-microglobulin gene. Nature. 302(5907). 449–452. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christopher Coleclough Breakdown of academic impact, for papers by I Hellström Breakdown of academic impact, for papers by Craig Okada Breakdown of academic impact, for papers by Gerard Folch Breakdown of academic impact, for papers by Irene Leung Breakdown of academic impact, for papers by Kay Stubenrauch Breakdown of academic impact, for papers by Aurelia Rughetti Breakdown of academic impact, for papers by Joann P. Palma Breakdown of academic impact, for papers by R A Reisfeld Breakdown of academic impact, for papers by Christopher Stebbins
Rankless by CCL
2026